Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Mohan Das
Clinical biochemistry is at the forefront of modern healthcare, providing critical insights into the diagnosis and management of various medical conditions. This abstract highlights key trends and developments in clinical biochemistry, focusing on emerging biomarkers and technologies that promise to revolutionize disease diagnosis and treatment. Recent advancements have led to the emergence of liquid biopsies, which enable non-invasive monitoring of disease progression through the analysis of circulating tumor DNA (ctDNA). Liquid biopsies offer real-time information for cancer management and are being explored for applications beyond oncology. MicroRNAs (miRNAs) have gained prominence as vital biomarkers associated with various diseases. Dysregulated miRNA profiles provide valuable information for early disease detection and monitoring, supporting more precise treatment strategies. Metabolomics, an evolving field, is transforming personalized medicine by identifying metabolic signatures that inform disease risk assessment and treatment optimization. Liquid Chromatography-Mass Spectrometry (LC-MS) technology plays a pivotal role in quantifying a wide range of biomolecules with high precision.